Safety of using the preparation “Licopid®” in opinion of experts in various specialities

Abstract

Aim. To study the safety of the preparation “Licopid®” using the data, obtained with the method of questioning of doctors of various specialities. The reactant of “Licopid®” tablets is glucoseminylmuramildipeptide – a synthetic analogue of the structural fragment of bacterial cells membrane (peptidoglycan), which is an activator of congenital and acquired immunity;it strengthens the defense of the body from viral, bacterial and fungal infections; it has an adjuvant effect in development of immunological reactions.

Materials and methods. The object of this study were the answers of 2315 specialists to the questions of surveys regarding the safety of using immunomodulator“Licopid®” in their practical activity. The regions, involved into the survey were the following cities: Moscow, Kazan, Krasnodar, Ekaterinburg, St. Petersburg, Chelyabinsk, Novosibirsk, Perm, Samara and Voronezh as well as Krasnodar Krai. Processing of the results was fulfilled with the methods of descriptive statistics; the obtained data were compared with the method based on calculation of chi-square criterion.

Results. The analyzed results showed that 962 respondents (41.5 %) indicated the fact of revealing undesirable reactions (UR) of the preparation “Licopid®” in their own practice. It was noted by them that all undesirable reactions were not severe and predicted, i.e. they were indicated in the instruction for medical use of “Licopid®” 1 mg and 10 mg.

Conclusions. While conducting questioning, the authors revealed statistically significant differences in the structure of respondents’ answers depending on the region of residence and medical speciality. At the same time, for all UR, indicated in instruction, subjectively estimated occurrence rate of reactions coincided with that, declared upon registration, except myalgias and arthralgias, which were noted by doctors much rarely.

Keywords

“Licopid®” / undesirable reactions / safety / doctors’ surveys / immunomodulators

References

[1] Боровиков В.П., Боровиков И.П. Статистический анализ и обработка данных в среде Windows. М.: Филинъ 1997; 608.

[2] Борщук Е.Л., Попов Ю.Н., Саньков А.Н. Анализ иммуномодуляторов на фармацевтическом рынке. Известия ОГАУ. 2016; 3 (59): 218–221.

[3] Исаков Д.В., Исаков В.А. Современная терапия социально значимых вирусных инфекций: метод. рекомендации. СПб. 2014.

[4] Милютина Л.Н., Голубев А.О. Опыт применения «Ликопид®» для санации постинфекционного сальмонеллезного бактерионосительства у детей. Российский вестник перинатологии и педиатрии 2015; 60 (4): 100–107.

[5] Сенцова Т.Б. Иммуномодуляторы в практике педиатра. Пульмонология и аллергология 2005; 3: 44–48.

[6] Стернин Ю.И., Кнорринг Г.Ю. Системная иммунотерапия в педиатрической практике. Практика педиатра. М. 2010; 14–15.

[7] Хаитов Р.М., Пинегин Б.В. Иммуномодуляторы: определение, классификация, механизмы действия и области клинического применения. Иммунотерапия: руководство для врачей. Под ред. Р.М. Хаитова, Р.И. Атауллаханова. М. 2011; 27.

[8] Ярмолинская М.И., Тарасова М.А., Селютин А.В., Денисова В.М., Толпыгина М.Г., Сельков С.А. Патогенетическое обоснование применения иммуномодулятора «Галавит» в терапии наружного генитального эндометриоза. Журнал Российского общества акушеров-гинекологов 2008; 4: 29–30.

[9] Antsiferova Y., Sotnikova N., Parfenyuk E. Different effects of the immunomodulatory drug GMDP immobilized onto aminopropyl modified and unmodified mesoporous silica nanoparticles upon peritoneal macrophages of women with endometriosis BioMed Research International 2013; 2013: Article ID 924362. DOI: 10.1155/2013/924362

[10] Janeway C.A.Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 1989; 54 (1): 1–13.

[11] Krensky A.M., Bennett W.M., Vincenti F. Chapter 35. Immuno-suppressants, tolerogens, and immunostimulants. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 12th ed. McGraw-Hill Professional 2011; 1991.

[12] Spitzer W.O. Pharmacoepidemiology: barriers and bridges. Tribute to Irene Guggenmoos-Holzmann. J Clin Epidemiol 1999; 52 (4): 351–354.

RIGHTS & PERMISSIONS

Krasheninnikov A.E., Matveev A.V., Andronova T.M., Guryanova S.V., Shilova N.V., Kozlov I.G.